UNIGE document Scientific Article - Letter
previous document  unige:20450  next document
add to browser collection

Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis

Dudler, Jean
Kyburz, Diego
Langenegger, Thomas
Moller, Burkhard
Schmiedel, Ute
Walker, Ulrich A.
Published in Schweizerische medizinische Wochenschrift. 2010, vol. 140, p. w13073
Abstract Rituximab is an effective treatment of rheumatoid arthritis (RA), which has been approved for the treatment of moderate to severe disease in patients with an inadequate response to anti-TNF therapies. Rituximab differs from other available biological agents for RA by way of its unique mode of action and unrivalled long dosing interval. The efficacy of rituximab subsides progressively over time and re-therapy is generally required to maintain long term disease control. The timing of re-treatment is currently not well established and varies widely in clinical practice. The present document is a concise recommendation regarding re-treatment with rituximab, based on validated outcomes such as the DAS28 and the EULAR response criteria. The recommendation was established through consensus between practitioners familiar with rituximab therapy in RA. Optimisation of the rituximab re-treatment schedule may improve patient outcomes and balance risks and benefits for the individual patient.
Keywords Antibodies, Monoclonal, Murine-Derived/adverse effects/*therapeutic useAntirheumatic Agents/adverse effects/*therapeutic useArthritis, Rheumatoid/*drug therapy/psychologyDose-Response Relationship, DrugDrug Administration ScheduleEvidence-Based Medicine/*standardsFollow-Up StudiesHumansQuality of Life/psychologyRetreatmentRisk AssessmentSwitzerlandTreatment Outcome
PMID: 20648402
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
Research group Mécanisme de l'inflammation articulaire (44)
(ISO format)
DUDLER, Jean et al. Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. In: Schweizerische medizinische Wochenschrift, 2010, vol. 140, p. w13073. doi: 10.4414/smw.2010.13073 https://archive-ouverte.unige.ch/unige:20450

399 hits

0 download


Deposited on : 2012-05-22

Export document
Format :
Citation style :